Completed OBSERVATIONAL NCT07239102
Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
A Real-World Clinical Retrospective Study of Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
Sponsor: Beijing Tiantan Hospital
Conditions
Central Nervous System Metastasis EGFR Positive Non-small Cell Lung Cancer Leptomeningeal Metastasis
Interventions
Firmonertinib
Updated 1 time since 2025 Last updated: Nov 16, 2025 Started: Jan 1, 2020 Primary completion: May 1, 2025 Completion: Oct 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This observational or N/A phase trial investigates Central Nervous System Metastasis and EGFR Positive Non-small Cell Lung Cancer and is currently completed. Beijing Tiantan Hospital leads this study, which shows 1 recorded version since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Completed
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Beijing Tiantan Hospital
Data source: Beijing Tiantan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .